Ronald Stafford Watts
Direktor/Vorstandsmitglied bei Wenkart Foundation
Profil
Ronald Stafford Watts is currently the Director at Wenkart Foundation and a Non-Executive Director at Biosceptre International Ltd.
He previously worked as a Non-Executive Director at Biosceptre (Aust) Pty Ltd.
and as a Non-Executive Director at Energy Action Ltd.
from 2003 to 2017.
He holds a doctorate degree from the University of Cambridge and an undergraduate degree from The University of New South Wales.
Aktive Positionen von Ronald Stafford Watts
| Unternehmen | Position | Beginn |
|---|---|---|
| Wenkart Foundation | Direktor/Vorstandsmitglied | - |
Biosceptre International Ltd.
 Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Ronald Stafford Watts
| Unternehmen | Position | Ende |
|---|---|---|
| ENERGY ACTION LIMITED | Vorsitzender | 12.11.2015 |
Biosceptre (Aust) Pty Ltd.
 Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Direktor/Vorstandsmitglied | - |
Ausbildung von Ronald Stafford Watts
| University of Cambridge | Doctorate Degree |
| The University of New South Wales | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ENERGY ACTION LIMITED | Commercial Services |
| Private Unternehmen | 3 |
|---|---|
Biosceptre (Aust) Pty Ltd.
Biosceptre (Aust) Pty Ltd. Pharmaceuticals: MajorHealth Technology Biosceptre (Aust) Pty Ltd. develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company was founded in 2000 and is headquartered in North Ryde, Australia. | Health Technology |
| Wenkart Foundation | |
Biosceptre International Ltd.
Biosceptre International Ltd. BiotechnologyHealth Technology Part of Biosceptre (Aust) Pty Ltd., Biosceptre International Ltd. is a biopharmaceutical company based in Babraham, UK. The British company is focused on developing their BRiDGECAR™ system, which combines nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. The company's researchers are pioneers in cancer therapeutic development, with a vision of targeted treatment for millions of cancer patients across the world. The company's multi-targeted BRiDGECAR™ system has the potential to benefit a range of malignancies and make a drastic difference to the lives of millions of cancer patients. The company's advisory board includes Sir Gregory Winter, a 2018 Nobel Prize winner in Chemistry. | Health Technology |
